High cervical spinal cord injury patients differ from both other groups in their lack of peripheral feedback and their inability to show motor approach or withdrawal behavior. (content.iospress.com)
Asterias Biotherapeutics, Inc. (CA, USA) has announced that they have completely enrolling and dosing a total of 10 patients with complete cervical spinal cord injury (SCI) with OPC - 1. (regmednet.com)
«We are pleased to provide this update regarding our ongoing clinical trial of AST - OPC1 for the treatment of severe cervical spinal cord injuries in patients for whom there are no viable treatment options and a high unmet medical need,» stated Michael Mulroy, President and Chief Executive Officer. (asteriasbiotherapeutics.com)